GlassScriptPhysician profile
Lucas L Catt
NPI 1912174970
$13,202.73
in general payments reported to CMS, 2019-2025
44 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,202 · 2020: $2,207 · 2021: $2,512 · 2022: $1,966 · 2023: $1,700 · 2024: $1,593 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,317.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,292.96 | 2019-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,282.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,175.41 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $1,140.47 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $946.21 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $763.28 | 2019-2025 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $620.07 | 2019-2022 | |
| Mylan Specialty L.P. | $412.07 | 2020-2024 | Yupelri |
| Amarin Pharma, INC. | $398.58 | 2019-2022 | |
| Pfizer INC. | $380.13 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $370.04 | 2019-2025 | Capvaxive, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $364.16 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $310.75 | 2019-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $239.92 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.63 | 2019-2023 | Xifaxan |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucas Catt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.